230 related articles for article (PubMed ID: 23208045)
1. [Development of an ultrasound-mediated nucleic acid delivery system for treating muscular dystrophies].
Negishi Y; Hamano N; Shiono H; Akiyama S; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Yakugaku Zasshi; 2012; 132(12):1383-8. PubMed ID: 23208045
[TBL] [Abstract][Full Text] [Related]
2. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
3. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy in large animal models of muscular dystrophy.
Wang Z; Chamberlain JS; Tapscott SJ; Storb R
ILAR J; 2009; 50(2):187-98. PubMed ID: 19293461
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
7. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
8. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
Jarmin S; Kymalainen H; Popplewell L; Dickson G
Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches to muscular dystrophy.
Goyenvalle A; Seto JT; Davies KE; Chamberlain J
Hum Mol Genet; 2011 Apr; 20(R1):R69-78. PubMed ID: 21436158
[TBL] [Abstract][Full Text] [Related]
10. [Mutation-specific treatments for Duchenne muscular dystrophy].
Matsuo M; Takeshima Y
Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic exon skipping for dysferlinopathies?
Aartsma-Rus A; Singh KH; Fokkema IF; Ginjaar IB; van Ommen GJ; den Dunnen JT; van der Maarel SM
Eur J Hum Genet; 2010 Aug; 18(8):889-94. PubMed ID: 20145676
[TBL] [Abstract][Full Text] [Related]
12. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
13. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for muscular dystrophy: lessons learned and path forward.
Mendell JR; Rodino-Klapac L; Sahenk Z; Malik V; Kaspar BK; Walker CM; Clark KR
Neurosci Lett; 2012 Oct; 527(2):90-9. PubMed ID: 22609847
[TBL] [Abstract][Full Text] [Related]
15. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy.
Mann CJ; Honeyman K; McClorey G; Fletcher S; Wilton SD
J Gene Med; 2002; 4(6):644-54. PubMed ID: 12439856
[TBL] [Abstract][Full Text] [Related]
16. [Development of gene delivery system into skeletal muscles by bubble liposomes and ultrasound].
Negishi Y; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Yakugaku Zasshi; 2010 Nov; 130(11):1489-96. PubMed ID: 21048408
[TBL] [Abstract][Full Text] [Related]
17. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.
Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Steinhaus JP; Moulton HM; Iversen PL; Wilton SD
Mol Ther; 2007 Sep; 15(9):1587-92. PubMed ID: 17579573
[TBL] [Abstract][Full Text] [Related]
18. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
Williams JH; Sirsi SR; Latta DR; Lutz GJ
Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
[TBL] [Abstract][Full Text] [Related]
19. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
Popplewell LJ; Malerba A; Dickson G
Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.
Madden HR; Fletcher S; Davis MR; Wilton SD
Hum Mutat; 2009 Jan; 30(1):22-8. PubMed ID: 18570328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
